{"id":"placebo-sitagliptin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebo sitagliptin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:33:20.939118+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:33:28.635394+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebo sitagliptin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:33:29.508219+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dipeptidyl peptidase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:33:30.096763+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201174/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:33:29.993210+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo sitagliptin is a non-active comparator used in randomized controlled trials to assess the efficacy of active sitagliptin (a DPP-4 inhibitor). It allows researchers to distinguish genuine drug effects from placebo response and natural disease progression. The formulation is identical in appearance and administration to active sitagliptin but lacks the active ingredient.","oneSentence":"Placebo sitagliptin is an inert formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient and produces no therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:21.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:33:31.787752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control arm (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT02363335","phase":"PHASE1","title":"The Role of Phosphodiesterase Inhibitors in Incretin Secretion","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2015-02-13","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT06813014","phase":"PHASE4","title":"Pharmacogenetics of Response to Sitagliptin (PRS)","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-12","conditions":"Diabetes","enrollment":400},{"nctId":"NCT06914102","phase":"","title":"Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-01-14","conditions":"Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":58387},{"nctId":"NCT06914154","phase":"","title":"Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-01-14","conditions":"Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":11265},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT04323189","phase":"PHASE4","title":"Effects of Sitagliptin in Individuals With Genetically Decreased DPP4","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-08-26","conditions":"Genetics Disease, Type2 Diabetes, Heart Failure","enrollment":20},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT07076056","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-10-27","conditions":"Type 2 Diabetes","enrollment":230},{"nctId":"NCT06770894","phase":"PHASE3","title":"DPP4-Inhibitors and Bone Metabolism in Diabetes","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2019-09-24","conditions":"Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2","enrollment":132},{"nctId":"NCT05900531","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers","status":"COMPLETED","sponsor":"Kallyope Inc.","startDate":"2022-09-21","conditions":"Obesity","enrollment":60},{"nctId":"NCT06054815","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2023-09-14","conditions":"NON-ALCOHOLIC STEATOHEPATITIS","enrollment":109},{"nctId":"NCT02452632","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT04017832","phase":"PHASE3","title":"A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1441},{"nctId":"NCT00936663","phase":"PHASE4","title":"Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-07-06","conditions":"Type 2 Diabetes, End Stage Renal Disease","enrollment":3},{"nctId":"NCT01951339","phase":"NA","title":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":"Type 2 Diabetes, Cardiovascular Disease","enrollment":36},{"nctId":"NCT05219409","phase":"PHASE2, PHASE3","title":"Effects of Sitagliptin in Relatives of T1D Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Milan","startDate":"2023-07","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT01928199","phase":"PHASE4","title":"Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-09","conditions":"Posttransplant Diabetes Mellitus","enrollment":61},{"nctId":"NCT02697253","phase":"PHASE2","title":"Mechanisms Underlying Predictors of Success From Obesity Surgery","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT05195944","phase":"PHASE4","title":"Semaglutide vs Sitagliptin","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2022-10-26","conditions":"Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis","enrollment":140},{"nctId":"NCT03101930","phase":"PHASE4","title":"Cardiovascular Effects of GLP-1 Receptor Activation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-05-01","conditions":"Obesity, PreDiabetes","enrollment":329},{"nctId":"NCT01485614","phase":"PHASE3","title":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-10","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":200},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT00650143","phase":"PHASE2, PHASE3","title":"Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-03","conditions":"Acute Myocardial Infarction","enrollment":174},{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766},{"nctId":"NCT04982705","phase":"PHASE1","title":"IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2021-07-07","conditions":"Type 2 Diabetes","enrollment":94},{"nctId":"NCT00659711","phase":"NA","title":"The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-03","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT02607865","phase":"PHASE3","title":"Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-02-15","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1864},{"nctId":"NCT01741103","phase":"NA","title":"Sitagliptin in Type I Diabetic Patients","status":"WITHDRAWN","sponsor":"University at Buffalo","startDate":"2011-06","conditions":"Diabetes Type I","enrollment":""},{"nctId":"NCT01879228","phase":"NA","title":"Effect of Chronic Incretin-based Therapy in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-06","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":26},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT00790205","phase":"PHASE3","title":"Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-10","conditions":"Type 2 Diabetes Mellitus","enrollment":14671},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT03893526","phase":"PHASE4","title":"Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2019-01-25","conditions":"Type2 Diabetes","enrollment":12},{"nctId":"NCT02683187","phase":"PHASE1","title":"DPP4 Inhibition & Beta Cell Function","status":"COMPLETED","sponsor":"David D'Alessio, M.D.","startDate":"2017-03-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT04268563","phase":"PHASE1, PHASE2","title":"Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-10","conditions":"Polycystic Ovary Syndrome, Infertility, ART","enrollment":80},{"nctId":"NCT03845179","phase":"NA","title":"GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2019-05-29","conditions":"Type2 Diabetes","enrollment":12},{"nctId":"NCT03061214","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-08-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":868},{"nctId":"NCT03359590","phase":"PHASE2","title":"Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2018-03-21","conditions":"Pharmacological Action","enrollment":20},{"nctId":"NCT00627744","phase":"PHASE4","title":"Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2008-05","conditions":"Myocardial Infarction, Unstable Angina Pectoris, Diabetes Mellitus","enrollment":85},{"nctId":"NCT03646721","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-08-29","conditions":"Diabetes Mellitus, Type 2","enrollment":108},{"nctId":"NCT00860288","phase":"PHASE2, PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1988},{"nctId":"NCT01619332","phase":"PHASE1, PHASE2","title":"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Type II Diabetes","enrollment":220},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT02377388","phase":"PHASE3","title":"DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-02-07","conditions":"Platelet Aggregation During Acute Myocardial Infarction","enrollment":74},{"nctId":"NCT01490918","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":165},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":"Psoriasis, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02536248","phase":"PHASE3","title":"Sitagliptin Therapy and Kinetics of Inflammatory Markers","status":"COMPLETED","sponsor":"Laval University","startDate":"2015-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02122380","phase":"PHASE4","title":"The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-02","conditions":"Polycystic Ovary Syndrome","enrollment":23},{"nctId":"NCT01405911","phase":"PHASE2","title":"Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-08-16","conditions":"Glucose Intolerance","enrollment":242},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT02111096","phase":"PHASE2","title":"A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":174},{"nctId":"NCT04061473","phase":"NA","title":"Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2019-04-02","conditions":"Diabetes After Total Pancreatectomy","enrollment":20},{"nctId":"NCT01703221","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":414},{"nctId":"NCT02576288","phase":"PHASE2","title":"Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2016-01","conditions":"Atherosclerosis, Inflammation","enrollment":21},{"nctId":"NCT03717688","phase":"PHASE4","title":"The Effects of Neprilysin on Glucagon-like Peptide-1","status":"COMPLETED","sponsor":"Nicolai Jacob Wewer Albrechtsen","startDate":"2018-05-17","conditions":"Diabetes, Heart Failure","enrollment":19},{"nctId":"NCT01930188","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1231},{"nctId":"NCT00094757","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10-06","conditions":"Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT00673894","phase":"NA","title":"Effects of Glutamine on GLP-1 and Insulin Secretion in Man","status":"COMPLETED","sponsor":"Garvan Institute of Medical Research","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02333591","phase":"PHASE4","title":"Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults","status":"COMPLETED","sponsor":"Mette Zander","startDate":"2016-07","conditions":"Coronary Microvascular Dysfunction","enrollment":25},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02256189","phase":"PHASE4","title":"Sitagliptin and Glucagon Counterregulation","status":"COMPLETED","sponsor":"Lund University","startDate":"2015-04","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT02628392","phase":"NA","title":"A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-11","conditions":"Type2 Diabetes Mellitus","enrollment":368},{"nctId":"NCT02685345","phase":"PHASE2","title":"A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT01512797","phase":"NA","title":"Treatment of Diabetes After Gastric Bypass With Sitagliptin","status":"COMPLETED","sponsor":"Blandine Laferrere","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":37},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01907854","phase":"PHASE4","title":"Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":407},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT02577003","phase":"PHASE3","title":"Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-09","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT02577016","phase":"PHASE3","title":"Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-05","conditions":"Type 2 Diabetes Mellitus","enrollment":141},{"nctId":"NCT02639637","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Vasoconstriction","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT03115099","phase":"PHASE1","title":"A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-05-31","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01545388","phase":"PHASE3","title":"Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":337},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01462266","phase":"PHASE3","title":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-13","conditions":"Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT01590797","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT02689362","phase":"PHASE2","title":"Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2017-08-08","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT02328040","phase":"PHASE1","title":"Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2014-09","conditions":"Diabetes Mellitus, Type 1","enrollment":17},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT03593135","phase":"NA","title":"Effect of Apple Cider Vinegar in Type 2 Diabetics","status":"COMPLETED","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2017-07-15","conditions":"Randomized Controlled Trial, Diabetes Mellitus","enrollment":126},{"nctId":"NCT01530178","phase":"PHASE4","title":"Sitagliptin Dose Determination Study","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 1","enrollment":8},{"nctId":"NCT02294084","phase":"PHASE4","title":"Sitagliptin and Brown Adipose Tissue","status":"COMPLETED","sponsor":"Ingrid Jazet","startDate":"2014-03","conditions":"Neoplasms, Adipose Tissue","enrollment":30},{"nctId":"NCT02741687","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-06","conditions":"Hyperglycemia","enrollment":80},{"nctId":"NCT00888238","phase":"PHASE1","title":"A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT00967798","phase":"PHASE3","title":"Prevention of Cystic Fibrosis Diabetes","status":"TERMINATED","sponsor":"Emory University","startDate":"2010-05","conditions":"Cystic Fibrosis, Prediabetes","enrollment":33},{"nctId":"NCT02513771","phase":"PHASE2","title":"Sitagliptin for Reducing Inflammation and Immune Activation","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2015-09","conditions":"HIV-1 Infection","enrollment":90},{"nctId":"NCT01970462","phase":"PHASE4","title":"Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery","status":"TERMINATED","sponsor":"Kathleen Dungan","startDate":"2014-01","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia","enrollment":8},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT01701973","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Growth Hormone Secretion","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2013-01","conditions":"Obesity","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201174"},"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo sitagliptin","genericName":"placebo sitagliptin","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo sitagliptin is an inert formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient and produces no therapeutic effect. Used for Clinical trial control arm (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:33:31.787752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}